abrdn Life Sciences Investors (abrdn Life Sciences Investors) Growth Rank : 0 (As of Apr. 29, 2024)

View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Growth Rank?

abrdn Life Sciences Investors has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

abrdn Life Sciences Investors Growth Rank Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103

Website

https://www.abrdnhql.com

abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.

Executives

Todd Reit	director	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher	director	600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino	director	C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor	other: Director of Adviser	C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc.	other: Adviser	1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick	other: Director of Adviser	C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar	officer: VP and Chief Legal Officer	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols	other: Director of Adviser	1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard	officer: President	ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy	officer: Secretary and Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari	officer: Treasurer and CFO	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson	officer: Vice President	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina	officer: Chief Compliance Officer & VP	1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird	director	388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022